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Abstract
Aims To undertake a feasibility randomized controlled trial of supported self-management vs treatment as usual in a
population of adults with obesity, Type 2 diabetes and an intellectual disability.
Methods We conducted an individually randomized feasibility trial. Participants were adults aged >18 years with a
mild or moderate intellectual disability, living in the community with Type 2 diabetes, on any therapy other than insulin.
Participants had mental capacity to consent to research and the intervention. Inclusion criteria included HbA1c > 48
mmol/mol (6.5%), BMI >25 kg/m2, or self-reported physical activity below national guideline levels. The experimental
intervention was standardized supported self-management delivered by diabetes specialist nurses plus treatment as usual,
compared with treatment as usual alone. Feasibility outcomes included: recruitment and retention; intervention
acceptability and feasibility; data collection and completeness for physiological state and values for candidate primary
outcomes (HbA1c and BMI).
Results A total of 82 participants (89% of those contacted and eligible) were randomized. All supported self-
management sessions were completed by 35/41 participants (85%); only four completed no sessions. Data on the follow-
up candidate primary outcomes HbA1c and BMI were obtained for 75/82 (91%) and 77/82 participants (94%),
respectively. The mean baseline HbA1c was 5616.5 mmol/mol (7.31.5%) and the mean BMI was 347.6 kg/m2.
Conclusions Adherence to supported self-management and willingness to have blood taken for outcome measurement
was good. A definitive randomized controlled trial is feasible in this population. (Trial registration: Current Controlled
Trials ISRCTN41897033)
Diabet. Med. 35, 776–788 (2018)
Introduction
It is estimated that ~1.5% of the population has a mild or
moderate intellectual disability. People with intellectual
disabilities have higher rates of Type 2 diabetes than the
general population [1–4], which is related to a high preva-
lence of obesity [5,6] and prescription medications that
increase diabetes risk. Higher rates of hospital admissions
from diabetes-related ambulatory-care-sensitive conditions
have been recorded in this population [4]. People with an
intellectual disability have difficulty understanding complex
information and learning new skills, combined with a
reduced ability to cope independently. This further affects
their ability to self-care [7].
Supported self-help or self-management for health prob-
lems is now reasonably well established [8–10]. Existing
approaches in people with intellectual disability are largely
educational and didactic, with little or nothing that facilitates
self-management, or have had problems with uptake [11].
Many adults with an intellectual disability do not live entirely
independently, even when living in the community [12,13],
but there is little content on the interaction between the
personwith diabetes and others supporting their care [14–18].
A definitive pragmatic phase III trial of a suitably designed
supported self-management is therefore indicated, but there
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remain feasibility questions to be addressed first. The present
trial, OK-DIABETES, was commissioned for this purpose.
Methods
Design, setting and objectives
We conducted an individually randomized, controlled, par-
allel-group feasibility trial of standardized supported self-
management delivered by diabetes specialist nurses plus
treatment as usual vs treatment as usual alone. An easy-read
booklet was provided in both study arms. The trial was based
in three sites around cities in West Yorkshire, UK.
The main study aims were: to estimate recruitment,
retention and follow-up rates for a definitive (phase III)
trial; to assess the acceptability and feasibility of implemen-
tation of the self-management intervention by measuring
adherence, drop-outs and negative outcomes (such as dis-
tress and agitation); to assess data collection and the
feasibility of collecting a range of physiological, psycholog-
ical, behavioural and cost-effectiveness outcome measures
and maintaining the blind for subjective outcomes; and to
measure variability in the candidate primary outcomes:
HbA1c and BMI.
Further details of the overall project are reported else-
where [19,20].
Participants and eligibility
Participants were eligible if they met all inclusion criteria:
age ≥18 years; current diagnosis of Type 2 diabetes not
requiring insulin therapy; mild or moderate intellectual
disability; mental capacity to consent to research participa-
tion; provision of written or verbal informed consent;
willingness to undergo a blood test and measurements for
HbA1c and BMI or, up-to-date (within 6 weeks) routine
values of HbA1c and BMI; suboptimal diabetes control,
defined as HbA1c >48 mmol/mol (> 6.5%); and BMI > 25kg/
m2 or physical activity below national guideline levels [21].
Participants were excluded if they: were referred for insulin
or put on insulin between identification and randomization;
were likely to require insulin in the next 3 months; were not
living in the community; or declined further assistance with
diabetes self-management.
‘Supporters’ were eligible if they met the operational
definition of ‘a key person in providing regular practical
support in diabetes self-management, who is in contact with
the person with diabetes at least weekly’ and gave informed
consent. We identified one main supporter for participants,
although other people could be included as ‘other helpers’.
Most referrals to a preliminary case-finding study came
from primary care physicians [22]. Baseline assessment at
face-to-face interview was assisted by participant informa-
tion and consent materials produced in an easy-read format.
An overview of randomization was provided in easy-read
format with a visual aid. Consent was obtained in writing,
or verbally if the participant did not want to, or could
not, write or make a mark (see Appendices S1, S2 for the
explanation of randomization and consent forms used for
participants). If present and willing, consent was obtained
from a key supporter.
Participants were randomized on a 1:1 basis to receive
supported self-management or treatment as usual using a
secure, automated 24-h telephone randomization service
based at the University of Leeds to ensure allocation
concealment. A computer-generated minimization algorithm
incorporating a random element accounting for: site (Leeds,
Bradford, Wakefield); supporter (none, not living with
supporter, living with supporter); HbA1c (≤48 mmol/mol,
>48 to 69 mmol/mol, >69 mmol/mol); BMI (≤25kg/m2,
>25kg/m2); and physical activity level below, at, or above
national guidelines (Fig. 1).
Intervention
Supported self-management
The intervention was based on modifying existing
approaches to supported self-management, with adjustments
made to respond to barriers to self-care in people with an
intellectual disability. It emphasized realistic goal setting,
identifying resources and barriers likely to influence success
in reaching goals, and regular self-monitoring of goal
attainment. For the ‘supported’ element we chose to use
face-to-face contact and employed two diabetes specialist
nurses from the local diabetes service, with no prior
experience in learning disability or involvement in research
concerning trials of complex interventions.
What’s new?
• This is the largest published randomized study of Type
2 diabetes mellitus self-management in community-
living adults with an intellectual disability.
• Recruitment was 89% of contacted eligible respon-
dents.
• Over 90% of randomized participants were retained in
the study, with primary outcome data collected at
follow-up.
• Adherence to self-management was good; 85% com-
pleted all sessions.
• HbA1c levels were in line with general population rates
for Type 2 diabetes.
• Obesity and physical inactivity were a major problem.
• We have demonstrated the feasibility of conducting a
definitive phase III trial in adults with an intellectual
disability.
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We started with three principles in deciding the format and
content of supported self-management. First the intervention
should respond to known barriers to self-management
reported by people with a disability, including practical
problems such as transport, likely attrition through drop-out
when multiple attendances are expected, and inability to
accommodate the presence of a supporter. Second, the
format of the intervention should be likely to encourage
self-maintained change beyond an early supported element;
in our target population this meant especially that the
intervention should involve supporters involved with any
aspect of lifestyle (shopping, food choice, physical activity,
medication monitoring and so on) relevant to diabetes.
Third, the intervention should be designed to be readily
integrated into usual healthcare provision in the National
Health Service, to ensure sustainability.
Based on all the advice we received from those working
with our target group, we wanted to give particular salience
to: practical aspects of self-care; use of simple (accessible)
written materials and charts; supportive contact both with a
professional and with a supporter if one could be identified;
use of practical goal setting and self-monitoring.
By contrast we decided that less helpful aspects would be
education of a more theoretical sort about the nature of
diabetes, food values and so on; however, all participants
received factual information about managing their diabetes
in a booklet as part of the treatment as usual arm of the
randomized controlled trial (https://www.diabetes.org.uk/ab
out_us/news/learning-disabilities-leaflet). We did not include
information technology-based interventions (e.g. web-,
DVD-, mobile phone-based interventions), because these are
usually not readily accessible by our participants. Finally, we
Agreed to contact for RCT
N=132 (89.8%)
Contacted for RCT
N=127 (96.2%)
Researcher visit conducted 
N=98 (77.2%)
Consent obtained during 
researcher visit 
N=92 (93.9%)
Randomized
N=82 (89.1%)
71    Nurse visit, blood test conducted 
5 Nurse visit, GP bloods records 
6 No nurse visit, GP blood records
Supported self-management N=41 (50%)
Follow-up
36 (87.8%)  Researcher & nurse follow-up
1 (2.4%)       Researcher follow-up only
4 (9.8%)      No follow-up
MSSM intervention
35 (85.4%) Completed all sessions 
2 (4.9%) Did not complete all sessions
4 (9.8%) Did not complete any sessions*
Consent not obtained: N=6 (6.1%)
2 Lacked capacity
1 Ineligible – treated with insulin 
1 Refused interview and blood tests 
1 Lacked capacity and refused blood tests
1 Refused interview, physical measures, blood tests, 
not interested 
Not contacted for RCT: N=5 (3.8%)
2 Unable to make contact 
2 Not approached
1 Died before contact made
No researcher visit: N=29 (22.8%)
14 Contacted but unable to visit / too busy
12 Visit declined 
3 Visit arranged but cancelled
Not randomised: N=10 (10.9%)
No nurse visit
• 4    Unable to contact / arrange nurse visit 
• 1    Changed mind prior to nurse visit 
Nurse visit conducted
• 2     Ineligible–no poor diabetes self-management
• 2     Refused essential measures 
• 1     Lacked capacity 
Eligible N=147Referred to case finding N=365
Unique referral 
N=325
Registered  
N=172
Treatment as usual N=41 (50%)
Follow-up
39 (95.1%)  Researcher & nurse follow-up
1 (2.4%)      Researcher follow-up only
1 (2.4%)      No follow-up
FIGURE 1 CONSORT flow chart for feasibility randomized controlled trial. GP, general practitioner.
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decided against group-based interventions as attendance is
typically poor and meeting the specific individual needs
arising in a heterogeneous population is harder in such
settings.
The final intervention had four standardized components
with associated materials. How they were delivered
depended on participant and supporter characteristics and
preferences.
(1)Establishing the participant’s daily routines and lifestyle.
Establishing the participant’s daily routines and lifestyle
included current diet and activity routines, participation
in daytime social activities or work, shopping and
food preparation, current self-reported health and self-
management. The main aim of this component was to
identify the social and personal influences in the life of the
person with diabetes that would limit their ability to self-
manage, or that might be mobilized as a resource in
supporting self-management.
(2)Identifying all supporters and helpers and their roles.
Identifying all supporters and helpers and their roles led to
key supporters and other helpers being given written
information about the project and if they agreed to
support a goal set by the participant they were given a
written reminder of their role. The main aim was to
identify people who might be a useful resource in
supporting self-management, and to ensure any changes
were embedded in the social network for longer-term
maintenance of change.
(3)Setting realistic goals for change. In setting realistic goals
for change the main aim was to avoid prescribing change
in the way of good dietary practice or other lifestyle
change, but to support goals suggested by the person with
diabetes that were specific, simple and achievable given
the person’s current routines and social support, and
consonant with their willingness to make change. The
intention was to encourage engagement in a population
usually thought of as having little agency, and to intro-
duce the idea of selectable elements in a repertoire of self-
management options.
(4)Monitoring progress against agreed upon goals. To allow
monitoring of progress against agreed upon goals we
devised a simple system that did not depend on high levels
of functional literacy, using tear-off calendar sheets on
which participants noted goal attainment in a Yes/No
format. The main aim was to encourage active participa-
tion in an activity that is a core feature of self-management.
We prepared materials to accompany these activities. For the
nurses we provided templates for a weekly timetable, a chart
to record friends and family and other helpers, charts to be
completed in collaboration with the person with diabetes
(‘my life’, ‘my likes and don’t likes’, ‘looking after my
diabetes’). For the person with diabetes there was an OK
Diabetes board to place in a prominent position at home with a
visible record of goals, including pictorial prompts, e.g. ‘snack
swaps’, a written action plan in multiple formats, and tear off
slips to record daily actions. For supporters and helpers we
provided an information sheet explaining the study and a
card summarizing what their role was in helping to support
the person with diabetes in meeting their chosen goals.
More detail on development of the intervention is reported
elsewhere [19].
Treatment as usual
Uncomplicated Type 2 diabetes is managed in primary care.
With our third-sector (voluntary sector, non-governmental)
partners we developed an accessible ‘easy-read’ information
booklet about Type 2 diabetes [http://www.easyhealth.
org.uk/listing/diabetes-(leaflets)] and provided it to all par-
ticipants.
Measures
Data were collected from medical notes by researcher
interview and nurse assessment. Researchers were blinded
for medical note review but, at follow-up, participants often
revealed the group they were in or were known to the
research nurse.
Outcomes related to feasibility of recruitment, retention
and comprehensiveness of outcome data were collected by
project researchers.
Outcomes related to intervention delivery and physiolog-
ical state (including candidate primary outcomes HbA1c and
BMI) were collected by nurses (where possible this was a
different nurse from the one delivering the intervention).
Outcomes related to other aspects of contact with clinical
services and clinical measures where a nurse visit was not
possible were obtained from primary care records.
Self-reported health economics questionnaire data, partic-
ipant mood, health-related quality of life, negative outcomes,
hospital attendances, physical activity and diet data were
collected through researcher interview. We found self-
reported physical activity too unreliable in this population
to use as an outcome measure, because, although people
were able to describe their daily routine in enough detail to
allow us to estimate that they were not meeting recom-
mended levels of activity, there was insufficient detail to
allow monitoring of change.
A 6-month follow-up was originally planned, but was
reduced for some to 4 months because of project deadlines. A
full list of outcome measures and how they were collected is
provided in Table 1.
Analysis
Progression criteria
We prespecified that if any of the following were met, a
definitive trial would be unfeasible: enrolment of ≤20
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participants after 6 months of recruitment; active or passive
withdrawal from follow-up of ≥40% of recruited partici-
pants; and ≥50% participants in the supported self-manage-
ment sessions attending no sessions.
Sample size
We planned to recruit 80 participants, randomized equally
between intervention and control arms, in order to obtain
follow-up data on at least 30 participants per arm [23],
assuming loss to follow-up would be no greater than 25% at
6 months. A formal power calculation was not appropriate
because effectiveness was not being evaluated. Estimates of
non-adherence [24] and loss to follow-up rates, and vari-
ability of candidate primary outcomes were intended to
inform power calculations for a definitive trial.
Analyses were conducted on the intention-to-treat popu-
lation using SAS version 9.4.
Data were summarized using descriptive summary statis-
tics and estimation with 95% CIs.
Feasibility and success of recruitment was evaluated
by summarizing the screening, eligibility, consent and
randomization processes, and evaluation included the num-
bers of participants involved at each stage and reasons for
non-participation.
We reported summary statistics for each treatment arm for
candidate primary outcomes and other physiological out-
comes at baseline and follow-up. To assess sensitivity to
change, we reported the distribution of outcomes and change
in BMI and HbA1c between baseline and follow-up, and
estimated the effect size in participants. Measures of diabetes
control, and metabolic complications are presented categor-
ically according to abnormal ranges on standard criteria.
Results
Of 147 initially eligible participants identified during case-
finding [22], 132 (90%) agreed to further research contact,
and 127/132 (96%) were contacted. More than three-
quarters of participants (98/127) agreed to be visited by the
researcher, and the majority (92/98) consented to take part in
the trial. A total of 82/92 people (89%) went on to be
randomized (Fig. 1).
Table 1 Assessments at baseline and follow-up in the randomized controlled trial
Medical notes
review /check
Pre-baseline
phone call
Baseline
research
interview
Baseline
research
nurse visit
6-month
medical/
research
nurse
follow-up
6-month
follow-up
research
interview
GP medical
notes
follow-up
Eligibility and consent
Presence and role of a supporter and/or
research advocate
X X
Mental capacity to consent to RCT X
Eligibility for RCT X X X
Consent for RCT X
Follow-up data
Negative outcomes X X
Related and unexpected
serious adverse events
X
Hospital attendances X X
Current physical health state (e.g. HbA1c,
blood pressure, BMI, weight, cholesterol,
HDL/LDL cholesterol, triglycerides, urea
and electrolytes, waist–hip ratio
X X X
Thyroid function, height X
Q Risk, retinal screening,
diabetes medication,
aerum creatinine, microalbuminuria
X
Details of treatment received X
Adherence to the intervention X
Prescribed diabetes regime (diet, exercise) X
Resource use: service and hospital usage X
Questionnaires (completed at researcher visit)
Health economics
questionnaire to cover health
and social care costs, participant and
supporter expenses and productivity costs
X X
Participant mood (PHQ-2) X X
Health-related quality of life (EQ5D-3L) X X
EQ5D-3L, three-level health-related quality-of-life instrument; GP, general practitioner; Patient Health Questionnaire-2; RCT, randomized
controlled trial.
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Characteristics of the study population
Participant demographics, including age, sex and ethnicity
were largely comparable to the case-finding population, and
were well balanced across trial arms (Table 2).
Table 3 gives details of the participants’ supporter and
living arrangements for the 82 people randomized.
Intervention delivery
Supported self-management
Forty-one participants (50%) were allocated to receive
supported self-management, of whom 35 (85%) completed
all required sessions, which ranged from two to four
sessions, with more than three-quarters of all participants
(78%) completing at least three sessions. Four partici-
pants (10%) did not complete any sessions. Thirty
participants (73%) had another person present with them
during at least one session.
Sessions mostly took place in the participant’s home
(92%). Sessions lasted a mean (range) of 45 (13–95) min,
and the focus included getting started, setting goals, mapping
supporter, and checking progress. Participants had a typical
total intervention time of 2 h.
A summary of engagement was reported by the nurse who
delivered the intervention: 23/40 participants (58%) were
deemed to be very engaged with the sessions and 12/40
(30%) with the materials; 15/41 (37%) were reported to
have a very engaged supporter; and 18/41 (44%) had a
further or different person engaged in intervention imple-
mentation.
Adherence and fidelity
Independent review of adherence and fidelity of the inter-
vention took place for all supported self-management
sessions completed (n=37).
All components of the supported self-management inter-
vention concerned with assessing day-to-day living arrange-
ments and diabetes management were covered in all the first
sessions, and at least some of these components were
revisited during the second session for 10/35 participants
(29%) completing at least two sessions.
Table 2 Characteristics and randomization stratification factors of participants
Case-finding study Feasibility trial randomized participants
Referred
population
N=325
Eligible
population
N=147
Supported
self-management
N=41
Treatment as usual
N=41
Total
N=82
Age at referral/registration N=22 missing
Mean (SD) 53.5 (13.81) 54.4 (12.82) 54.8 (10.83) 56.2 (12.46) 55.5 (11.62)
Median (range) 54.0 (18, 93) 56.0 (19, 83) 56.0 (29, 76) 57.0 (19, 79) 56.5 (19, 79)
Age at randomization
Mean (SD) 55.6 (10.75) 57.3 (12.26) 56.4 (11.49)
Median (range) 57.0 (30, 77) 58.0 (20, 79) 58.0 (20, 79)
Gender, n (%) n=14 missing
Male 174 (55.9) 74 (50.3) 20 (48.8) 20 (48.8) 40 (48.8)
Female 137 (44.1) 73 (49.7) 21 (51.2) 21 (51.2) 42 (51.2)
Ethnicity, n (%) N=22 missing
White 249 (82.2) 125 (85.0) 36 (87.8) 39 (95.1) 75 (91.5)
Mixed 6 (2.0) 3 (2.0) 2 (4.9) 0 (0.0) 2 (2.4)
Asian 45 (14.9) 17 (11.6) 3 (7.3) 2 (4.9) 5 (6.1)
Black 2 (0.7) 1 (0.7) 0 (0.0) 0 (0.0) 0 (0.0)
Other ethnic group 1 (0.3) 1 (0.7) 0 (0.0) 0 (0.0) 0 (0.0)
Randomization stratification factors, n (%)
Area
Leeds 18 (43.9) 18 (43.9%) 36 (43.9%)
Bradford 12 (29.3) 12 (29.3%) 24 (29.3%)
Wakefield 11 (26.8) 11 (26.8%) 22 (26.8%)
HbA1c
≤48 mmol/mol (≤6.5%) 15 (36.6) 16 (39.0%) 31 (37.8%)
>48 to 69 mmol/mol (>6.5 to 8.5%) 20 (48.8) 20 (48.8%) 40 (48.8%)
>69 mmol/mol (>8.5%) 6 (14.6) 5 (12.2%) 11 (13.4%)
BMI
≤25 kg/m2 1 (2.4) 2 (4.9) 3 (3.7)
>25 kg/m2 40 (97.6) 39 (95.1) 79 (96.3)
Physical activity
At or above national guidelines 1 (2.4) 0 (0.0) 1 (1.2)
Below national guidelines 40 (97.6) 41 (100.0) 81 (98.8)
Supporter available
No supporter 9 (22.0) 11 (26.8) 20 (24.4)
Participant does not live with supporter 23 (56.1) 22 (53.7) 45 (54.9)
Participant lives with supporter 9 (22.0) 8 (19.5) 17 (20.7)
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The most frequent goals identified were to increase
physical activity and to make dietary changes.
Outcome data collection
Retention/ loss to follow-up
After randomization, withdrawals (researcher or nurse
follow-up) were made for six participants (7%): four
allocated to supported self-management and two to treat-
ment as usual.
The follow-up researcher visit was conducted for 77
participants (94%). A baseline nurse visit was conducted
for 76 participants (93%) and was not required for five
participants as in-date physical measures were obtained
from their general practitioner (GP). It was also possible to
obtain GP records for a further participant who declined
the baseline nurse visit. Nurse follow-up was conducted for
75 participants (92%), with no visit for the six participants
who had withdrawn, and GP records were obtained for the
remaining participant.
Researcher follow-up took place a mean (range) of 4.4
(3–6.2) months after randomization, followed by nurse
visits at a mean (range) of 4.8 (4–8) months after
randomization.
Unblinding
The follow-up nurse was unblinded for 34 trial participants
(41%); 20 (49%) in the supported self-management arm
and 14 (34%) in treatment as usual arm. Researchers were
unblinded for 16 participants (20%; with all but one in the
supported self-management arm), all of which occurred
before the follow-up assessment.
Physical measures
For 14 participants at baseline and 13 at follow-up, results
could not be obtained during the nurse visit or because there
was no nurse visit. GP records were therefore obtained for
11/14 participants (79%) and 5/13 participants (38%),
respectively.
Statistical outcomes
The participants’ clinical characteristics at baseline and
follow-up are shown in Table 4 for HbA1c, BMI and all
other outcomes.
At baseline, participants had a mean  SD HbA1c of 56.1
 16.5 mmol/mol (7.3%), with 29 participants (35%) above
the threshold for desirable control [≥58 mmol/mol (7.5%)],
which were similar figures to those for the general population
with Type 2 diabetes in West Yorkshire [19].
Obesity posed a greater problem, with mean  SD BMI
among the study cohort of 34.07.6 kg/m2 and two-thirds
of participants classed as obese and 19% morbidly obese
(BMI≥40 kg/m2).
Candidate primary outcomes were similar across trial
arms at baseline and follow-up (Table 4); however, when
comparing within-participant reduction in HbA1c and BMI
in individuals with measures at baseline and follow-up, an
effect size in the supported self-management arm of 0.33
(0.5/1.5) was observed for BMI, and for HbA1c it was 0.30
(0.17/0.57), whilst minimal effects were observed in the
group receiving treatment as usual (Figs 2 and 3).
Scores for participant mood, obtained from the Patient
Health Questionnaire-2 (PHQ-2) [25] are shown in
Table 3 Participant details and living arrangements at baseline
Supported self-management
N=41
Treatment as usual
N=41
Total
N=82
Someone who helps/supports you with your diabetes in day to day life?*
Yes, n (%) 26 (63.4) 32 (78.0) 58 (70.7)
If yes, main person, n (%)
Paid supporter 16 (61.5) 24 (77.4) 40 (70.2)
Immediate family 7 (26.9) 5 (16.1) 12 (21.1)
Partner/husband/wife 1 (3.8) 1 (3.2) 2 (3.5)
Grown-up child of person 1 (3.8) 1 (3.2) 2 (3.5)
Other family member 1 (3.8) 0 (0.0) 1 (1.8)
Friend 0 (0.0) 0 (0.0) 0 (0.0)
Missing 0 1 1
Is there anyone who helps you with shopping and cooking?
Yes, n (%) 33 (80.5) 36 (87.8) 69 (84.1)
If yes, main person, n (%)
Paid supporter 20 (60.6) 22 (64.7) 42 (62.7)
Immediate family 7 (21.2) 8 (23.5) 15 (22.4)
Partner/husband/wife 2 (6.1) 1 (2.9) 3 (4.5)
Other family member 3 (9.1) 0 (0.0) 3 (4.5)
Grown-up child of person 1 (3.0) 2 (5.9) 3 (4.5)
Friend 0 (0.0) 1 (2.9) 1 (1.5)
Other relationship 0 (0.0) 0 (0.0) 0 (0.0)
Missing 0 2 2
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Table 4 Distribution of HbA1c, BMI, blood pressure, other measures and lipids at baseline and follow-up
Baseline Follow-up
Supported
self-management
N=41
Treatment
as usual
N=41
Total
N=82
Supported
self-management
N=41
Treatment
as usual
N=41
Total
N=82
HbA1c
mmol/mol
Missing 0 0 0 4 3 7
Mean (SD) 57 (15.1) 55 (18.0) 56 (16.5) 54 (13.5) 55 (19.5) 54 (16.7)
95% CI (52.2, 61.8) (49.60, 61.0) (52.5, 59.8) (49.5, 58.5) (48.2, 61.0) (50.5, 58.2)
%
Mean (SD) 7.4 (1.38) 7.2 (1.65) 7.3 (1.51) 7.1 (1.24) 7.1 (1.79) 7.1 (1.53)
95% CI (6.93, 7.80) (6.69, 7.73) (6.95, 7.62) (6.68, 7.51) (6.56, 7.73) (6.77, 7.47)
HbA1c category, n (%)
<48 mmol/mol (6.5%) 15 (36.6) 15 (36.6) 30 (36.6) 12 (32.4) 18 (47.4) 30 (40.0)
48 to <58 mmol/mol
(6.5 to <7.5%)
10 (24.4) 13 (31.7) 23 (28.0) 15 (40.5) 9 (23.7) 24 (32.0)
≥58 mmol/mol (7.5%) 16 (39.0) 13 (31.7) 29 (35.4) 10 (27.0) 11 (28.9) 21 (28.0)
Missing 4 3 7
BMI, kg/m2
Missing 1 0 1 4 1 5
Mean (SD) 33.8 (6.94) 34.3 (8.23) 34.0 (7.58) 34.2 (8.67) 34.1 (8.46) 34.1 (8.51)
95% CI (31.54, 35.98) (31.73, 36.93) (32.37, 35.72) (31.28, 37.06) (31.41, 36.82) (32.21, 36.07)
BMI category, n (%)
Normal: 18.5–24.9 kg/m2 1 (2.5) 1 (2.4) 2 (2.5) 3 (8.1) 1 (2.5) 4 (5.2)
Overweight: 25–29.9 kg/m2 11 (27.5) 14 (34.1) 25 (30.9) 10 (27.0) 14 (35.0) 24 (31.2)
Obese Class I: 30–34.9 kg/m2 14 (35.0) 9 (22.0) 23 (28.4) 9 (24.3) 10 (25.0) 19 (24.7)
Obese Class II: 35–39.9 kg/m2 7 (17.5) 9 (22.0) 16 (19.8) 7 (18.9) 6 (15.0) 13 (16.9)
Obese Class III: ≥40 kg/m2 7 (17.5) 8 (19.5) 15 (18.5) 8 (21.6) 9 (22.5) 17 (22.1)
Missing 1 0 1 4 1 5
Weight, kg
Missing* 2 5 7 5 2 7
Mean (SD) 89.6 (20.54) 90.5 (25.14) 90.0 (22.71) 91.4 (25.91) 87.2 (23.74) 89.2 (24.72)
95% CI (82.99, 96.30) (81.94, 98.96) (84.81, 95.26) (82.61, 100.1) (79.49, 94.88) (83.51, 94.89)
Systolic blood pressure, mmHg
Missing 2 1 3 4 3 7
Mean (SD) 127.8 (16.07) 125.7 (16.47) 126.7 (16.20) 119.4 (18.06) 122.6 (16.65) 121.1 (17.32)
95% CI (122.6, 133.0) (120.5, 131.0) (123.1, 130.4) (113.4, 125.5) (117.2, 128.1) (117.1, 125.0)
Systolic blood pressure category, n (%)
<140 mmHg 29 (74.4) 33 (82.5) 62 (78.5) 33 (89.2) 30 (78.9) 63 (84.0)
≥140 mmHg 10 (25.6) 7 (17.5) 17 (21.5) 4 (10.8) 8 (21.1) 12 (16.0)
Missing 2 1 3 4 3 7
Diastolic blood pressure, mmHg
Missing 2 1 3 4 3 7
Mean (SD) 78.7 (10.93) 77.7 (11.56) 78.2 (11.19) 76.3 (9.89) 74.6 (10.50) 75.4 (10.17)
95% CI (75.15, 82.23) (73.98, 81.37) (75.67, 80.68) (72.97, 79.57) (71.18, 78.08) (73.10, 77.78)
Diastolic blood pressure category
<80 mmHg 20 (51.3) 27 (67.5) 47 (59.5) 24 (64.9) 24 (63.2) 48 (64.0)
≥80 mmHg 19 (48.7) 13 (32.5) 32 (40.5) 13 (35.1) 14 (36.8) 27 (36.0)
Missing 2 1 3 4 3 7
Waist measurement, cm
Missing 1 6 7 5 2 7
Mean (SD) 112.5 (17.74) 109.2 (16.58) 110.9 (17.17) 113.0 (18.97) 109.2 (15.91) 111.0 (17.43)
95% CI (106.8, 118.1) (103.5, 114.9) (107.0, 114.9) (106.6, 119.4) (104.0, 114.3) (107.0, 115.0)
Waist circumference and risk
of metabolic complications†, n (%)
Not at increased risk 4 (10.0) 3 (8.6) 7 (9.3) 3 (8.3) 3 (7.7) 6 (8.0)
Increased risk 3 (7.5) 3 (8.6) 6 (8.0) 3 (8.3) 4 (10.3) 7 (9.3)
Substantially increased risk 33 (82.5) 29 (82.9) 62 (82.7) 30 (83.3) 32 (82.1) 62 (82.7)
Missing 1 6 7 5 2 7
Waist–hip ratio
Missing 1 6 7 5 2 7
Mean (SD) 0.93 (0.11) 0.92 (0.21) 0.93 (0.16) 0.96 (0.07) 0.93 (0.07) 0.94 (0.07)
95% CI (0.90, 0.97) (0.85, 0.99) (0.89, 0.96) (0.94, 0.98) (0.91, 0.95) (0.93, 0.96)
Waist: hip ratio and risk of
metabolic complications‡, n (%)
Not at increased risk 7 (17.5) 8 (22.9) 15 (20.0) 3 (8.3) 5 (12.8) 8 (10.7)
Substantially increased risk 33 (82.5) 27 (77.1) 60 (80.0) 33 (91.7) 34 (87.2) 67 (89.3)
Missing 1 6 7 5 2 7
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Table 5. Major depression (score ≥3) was indicated for 17/
70 participants (24%) at baseline, and 21/59 participants
(36%) at follow-up. Participants expressed difficulty
answering the PHQ-2 questions, with just under 50%
reporting some or extreme difficulty, those who found
the questions most difficult were no more likely to rate
above the threshold for likely major depressive disorder
(≥3).
We were able to obtain results from the three-level health-
related quality-of-life instrument, the EQ5D-3L, on 80
participants at baseline and 76 at follow-up (Table 6).
Safety
Unplanned hospital attendances were identified by the
research team for 10 participants (12%): four participants
Table 4 (Continued)
Baseline Follow-up
Supported
self-management
N=41
Treatment
as usual
N=41
Total
N=82
Supported
self-management
N=41
Treatment
as usual
N=41
Total
N=82
Total cholesterol, mmol/l
Missing 5 2 7 5 4 9
Mean (SD) 4.0 (0.85) 4.2 (1.06) 4.1 (0.96) 3.8 (0.90) 4.1 (1.07) 4.0 (0.99)
95% CI (3.76, 4.33) (3.84, 4.53) (3.90, 4.34) (3.52, 4.13) (3.77, 4.48) (3.75, 4.21)
Total cholesterol, n (%)
<4 mmol/l 17 (47.2) 19 (48.7) 36 (48.0) 21 (58.3) 18 (48.6) 39 (53.4)
≥4 mmol/l 19 (52.8) 20 (51.3) 39 (52.0) 15 (41.7) 19 (51.4) 34 (46.6)
Missing 5 2 7 5 4 9
Triglycerides, mmol/l
Missing 6 6 12 6 6 12
Mean (SD) 2.0 (1.15) 2.2 (1.36) 2.1 (1.25) 1.9 (1.04) 2.0 (1.12) 2.0 (1.07)
95% CI (1.65, 2.44) (1.68, 2.62) (1.80, 2.40) (1.58, 2.29) (1.60, 2.37) (1.71, 2.22)
Triglycerides category¶, n (%)
<4.5 mmol/l 33 (94.3) 33 (94.3) 66 (94.3) 34 (97.1) 34 (97.1) 68 (97.1)
4.5–9.9 mmol/l 2 (5.7) 2 (5.7) 4 (5.7) 1 (2.9) 1 (2.9) 2 (2.9)
Missing 6 6 12 6 6 12
eGFR, ml/min/1.73 m2
Missing 9 5 14 6 5 11
Number known only to be >90 17§ 23 40§ 22 23 45
Mean (SD) 67.3 (18.84) 66.5 (16.47) 66.9 (17.46) 68.4 (17.56) 69.1 (17.78) 68.7 (17.32)
95% CI (56.83, 77.70) (56.59, 76.49) (60.16, 73.70) (57.77, 79.00) (58.33, 79.82) (61.74, 75.73)
eGFR category, n (%)
Normal kidney function:
≥90 ml/min/1.73 m2
20 (62.5) 23 (63.9) 43 (63.2) 22 (62.9) 23 (63.9) 45 (63.4)
Mildly reduced kidney
function:
60–89 ml/min/1.73 m2
6 (18.8) 10 (27.8) 16 (23.5) 8 (22.9) 10 (27.8) 18 (25.4)
Moderately reduced kidney
function:
30–59 ml/min/1.73 m2
6 (18.8) 3 (8.3) 9 (13.2) 5 (14.3) 2 (5.6) 7 (9.9)
Severely reduced kidney
function:
<30 ml/min/1.73 m2
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.8) 1 (1.4)
Missing 9 5 14 6 5 11
Urea, mmol/l
Missing 9 3 12 8 6 14
Mean (SD) 6.0 (1.85) 6.2 (1.81) 6.1 (1.81) 6.1 (1.66) 6.0 (1.73) 6.1 (1.68)
95% CI (5.33, 6.66) (5.59, 6.78) (5.66, 6.53) (5.53, 6.71) (5.40, 6.58) (5.65, 6.46)
Creatinine, lmol/l
Missing 8 3 11 4 0 4
Mean (SD) 73.7 (24.49) 66.8 (24.02) 70.0 (24.32) 70.1 (24.89) 67.7 (26.64) 68.8 (25.68)
95% CI (65.01, 82.38) (58.89, 74.68) (64.24, 75.76) (61.78, 78.38) (59.30, 76.11) (63.04, 74.62)
eGFR, estimated GFR.
*There were more missing data for weight compared to BMI as where possible BMI (but not weight) was collected from the general
practioner where weight was not obtained at research visits.
†Waist circumference and risk of metabolic complications: not at increased risk: ≤94 cm (men), ≤80 cm (women); increased risk: >94 cm
(men), >80 cm (women); substantially increased risk: >102 cm (men), >88 cm (women).
‡Waist–hip ratio and risk of metabolic complications: not at increased risk: <90 cm (men), <85 cm (women); substantially increased risk: ≥90
cm (men), ≥85 cm (women).
§Reported eGFR was ≥90 ml/min/1.73 m2 for a further three participants in the supported self-management arm.
¶UK National Institute for Health and Care Excellence: Clinical Guideline CG181.
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receiving supported self-management and six participants
receiving treatment as usual. Hospital attendance (Accident
and Emergency department attendance or admission) was
reported by the participant’s GP for 12/66 participants
(18%); seven allocated to supported self-management and
five to treatment as usual. Of 66 participants, six (9%) had
attendances for non-diabetes physical illness, and one
participant with a previous psychiatric history had an
attendance for mental illness. On two occasions, nurses were
sufficiently concerned about the mental state of participants
to discuss the problem in supervision and subsequently to
contact the GP, both of whom were already in contact with
mental health services.
There was no report from either researchers or GPs
indicating that hospital contacts were attributable to
changes brought about either by research participation
or by exposure to the supported self-management interven-
tion. Participant qualitative interviews confirmed the opin-
ion that there were no untoward outcomes associated
with the intervention; participants were clear that they did
not regard contact with researchers or nurses as a stressor.
The participant advocacy service did not give us details of
individuals but told us they had received fewer than six
contacts and all were requests about changing appointment
times for research or nurse visits.
Discussion
We found that it was possible to identify eligible participants
in the target population and recruit them into the trial.
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Retention was excellent, with 85% of participants complet-
ing all intervention sessions and candidate primary out-
comes obtained in >90%. Furthermore, our concerns that
many participants would not allow blood samples to be
taken were unfounded. Conducting blood tests proved a
time-efficient method in comparison to seeking medical
record information from a participant’s GP, which is a
reflection of the number of contact attempts, low response
rates and high levels of missing data from GPs, despite a
large amount of researcher time spent contacting practices.
Our researchers and nurses were able to work effectively
with adults with a mild to moderate intellectual disability
despite not having previous experience in this area. By working
with a professional, accessible information organization and
our Patient and Public Involvement collaborators, we were
able to create accessible materials for information that
facilitated informed consent to a trial, and supported the
research process.
Obesity was a major problem, and was coupled with low
levels of self-reported physical activity. Given these findings,
glycaemic control was not as poor as we had expected.
Many of our participants reported dissatisfaction with
their diet and their weight, and it may be that this was an
important part of their expressed desire for help with their
diabetes management.
This is the largest published trial of supported self-
management for Type 2 diabetes in adults with an intellec-
tual disability. Participants were typical of those identified in
our initial case-finding study [22], and also (as far as we can
ascertain from published figures) of the wider population
with Type 2 diabetes and intellectual disability. Our choice
of diabetes nurses as therapists increases the prospects for
generalizability of our findings; in routine practice, adults
with milder intellectual disabilities are rarely seen in
specialist learning disability services. Unblinding of research
outcome assessment was high but, given the nature of the
candidate primary outcomes (BMI, HbA1c), was unlikely to
be a source of significant bias.
There were a number of limitations to the study. The
exclusion of people on insulin treatment was part of the
Table 5 Participant mood, assessed using the Patient Health Questionnaire-2
Baseline Follow-up
Supported
self-management
N=41
Treatment
as usual
N=41
Total
N=82
Supported
self-management
N=41
Treatment
as usual
N=41
Total
N=82
Little interest or pleasure doing things, n (%)
Not at all 27 (65.9) 28 (68.3) 55 (67.1) 22 (59.5) 33 (86.8) 55 (73.3)
Several days 9 (22.0) 9 (22.0) 18 (22.0) 10 (27.0) 2 (5.3) 12 (16.0)
More than half the days 3 (7.3) 3 (7.3) 6 (7.3) 1 (2.7) 0 (0.0) 1 (1.3)
Nearly every day 2 (4.9) 1 (2.4) 3 (3.7) 4 (10.8) 3 (7.9) 7 (9.3)
Missing 0 0 0 4 3 7
Feel down, depressed, n (%)
Not at all 11 (32.4) 15 (41.7) 26 (37.1) 8 (26.7) 18 (60.0) 26 (43.3)
Several days 15 (44.1) 15 (41.7) 30 (42.9) 7 (23.3) 6 (20.0) 13 (21.7)
More than half the days 3 (8.8) 3 (8.3) 6 (8.6) 5 (16.7) 2 (6.7) 7 (11.7)
Nearly every day 5 (14.7) 3 (8.3) 8 (11.4) 10 (33.3) 4 (13.3) 14 (23.3)
Missing 7 5 12 11 11 22
PHQ-2 Score, n (%)
Missing 7 5 12 11 12 23
Mean (SD) 1.7 (1.66) 1.3 (1.51) 1.5 (1.59) 2.4 (1.87) 1.1 (1.80) 1.7 (1.93)
Median (range) 1.0 (0, 6) 1.0 (0, 6) 1.0 (0, 6) 2.5 (0, 6) 0.0 (0, 6) 1.0 (0, 6)
PHQ-2 score: major depression, n (%)
Not indicated (<3) 24 (70.6) 29 (80.6) 53 (75.7) 15 (50.0) 23 (79.3) 38 (64.4)
Indicated (≥3) 10 (29.4) 7 (19.4) 17 (24.3) 15 (50.0) 6 (20.7) 21 (35.6%)
Missing 7 5 12 11 12 23
Difficult answering PHQ-2, n (%)
No difficulty 24 (60.0) 23 (56.1) 47 (58.0) 20 (54.1) 19 (50.0) 39 (52.0)
Some difficulty 15 (37.5) 17 (41.5) 32 (39.5) 16 (43.2) 13 (34.2) 29 (38.7)
Extreme difficulty 1 (2.5) 1 (2.4) 2 (2.5) 1 (2.7) 6 (15.8) 7 (9.3)
Missing 1 0 1 4 3 7
PHQ-2, Patient Health Questionnaire-2.
Table 6 Three-level health-related quality-of-life instrument, EQ-5D-
3L, at baseline and follow up
Baseline
N=82
Follow-up
N=82
EQ-5D-3L score
Missing 2 6
Mean (SD) 0.67 (0.288) 0.66 (0.346)
Median (range) 0.73 (0.24, 1) 0.79 (0.24, 1)
Interquartile range (0.60–0.85) (0.43–1)
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funder’s commissioning brief, but in retrospect led to the
omission of a substantial proportion of the target population
with the worst glycaemic control and therefore potentially
the most to gain from an intervention.
It also proved more difficult than anticipated to obtain the
sustained participation of key supporters. Although most
participants could name a supporter, in only a minority did
that person have regular, engaged involvement with the
intervention. A familiar scenario was the participant living in
a shared house with other adults with an intellectual
disability and paid staff providing support; supporters then
changed day-by-day according to shifts or the use of agency
staff.
Characterizing usual care was problematic. Informal
supportive contacts in primary care, where most support
for Type 2 diabetes occurs, are unlikely to be recorded and
recollection of our participants was unlikely to be robust
enough for research purposes.
Two further limitations were specific to the intervention.
One is the number of face-to-face sessions involved. Recent
reviews suggest that the number of sessions/hours of
personal contact is an important determinant of success in
changing risks for diabetes onset or cardiovascular disease
[26–30]. Effective interventions for adults with an intellec-
tual disability probably involve more therapeutic contact
than is usual in standard approaches to self-management,
and more than we offered in the present trial, even though,
with a planned four sessions, our intervention involved more
contact than is available in many self-management
programmes. The second characteristic of our intervention
was its emphasis on diabetes self-management in a broadly
defined sense rather than specifically on weight reduction
through a calorie-deficit diet. Given the centrality of obesity
to Type 2 diabetes and its very high prevalence in our
population this may have been a limitation
A clinically important reduction in HbA1c is usually taken
to be 5 mmol/mol (0.5%) which is equivalent to an effect
size of 0.3 (based on our SD of 16.5). For a definitive trial to
have 90% power (two-sided a = 0.05), a sample size of 194
per arm would be required after accounting for loss to
follow-up and potential clustering. An alternative approach
may be to focus research on establishing the effectiveness
of treatments that reduce obesity and target the high levels
of sedentary behaviour in this group.
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